Patents by Inventor Alan Knutsen

Alan Knutsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating mucopolysaccharidosis type IVA
    Patent number: 11844825
    Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: December 19, 2023
    Assignee: Saint Louis University
    Inventors: Adriana M. Montaño-Suarez, Angela Catalina Sosa-Molano, Alan Knutsen, Clifford Bellone, Shunji Tomatsu, Luis Barrera
  • Method of treating mucopolysaccharidosis type IVA
    Patent number: 11529397
    Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: December 20, 2022
    Assignee: Saint Louis University
    Inventors: Adriana M. Montaño-Suarez, Angela Catalina Sosa-Molano, Alan Knutsen, Clifford Bellone, Shunji Tomatsu, Luis Barrera
  • METHOD OF TREATING MUCOPOLYSACCHARIDOSIS TYPE IVA
    Publication number: 20210260172
    Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 26, 2021
    Inventors: Adriana M. Montaño-Suarez, Angela Catalina Sosa-Molano, Alan Knutsen, Clifford Bellone, Shunji Tomatsu, Luis Barrera
  • METHOD OF TREATING MUCOPOLYSACCHARIDOSIS TYPE IVA
    Publication number: 20190224283
    Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.
    Type: Application
    Filed: January 22, 2018
    Publication date: July 25, 2019
    Inventors: Adriana M. Montaño-Suarez, Angela Catalina Sosa-Molano, Alan Knutsen, Clifford Bellone, Shunji Tomatsu, Luis Barrera